Babl FE, Regan AM & Pelton SI (1999) Abnormal body-fat distribution in HIV-1 infected children on antiretrovirals. Lancet 353, 1243–1244.
Batterham MJ, Garsia R & Greenop P (1999) Measurement of body composition in people with HIV/AIDS: a comparison of bioelectrical impedance and skinfold anthropometry with dual-energy x-ray absorptiometry. Journal of American Dietetic Association 99, 1109–1111.
Baum MK, Shor-Posner G & Lai S (1997) High-risk of HIV-related mortality is associated with selenium deficiency. Journal of Acquired Immunodeficiency and Human Retrovirology 5, 370–374.
Baum MKet al. (1998) Micronutrient status in relationship to mortality in HIV-1 disease. Nutrition Reviews 56, S135–S139.
Baumgartner RN, Chumlea WC & Roche AF (1989) Estimation of body composition for bioelectric impedance of body segments. American Journal of Clinical Nutrition 50, 221–226.
Behrens G, Schmidt H & Meyer D (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1958.
Behrens G, Dejam A, Schmidt H, Belks HJ, Brabnt G, Korner T, Stoll M & Schmidt RE (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13, 63–70.
Bell PM & Hadden DR (1997) Metformin. Endocrinology and Metabolism Clinics of North America 26, 523–537.
Berger B, Ollenschlager G, Schrappe M, Stute A, Fischer M, Wessel D, Schwenk A & Diehl V (1993) Nutrition behavior of malnourished HIV-infected patients and intensified oral nutritional intervention. Nutrition 9, 43–44.
Berger J, Pall L, Hall C, Simpson D, Berry P & Dudley R (1996) Oxandrolone in AIDS-wasting myopathy. AIDS 10, 1657–1662.
Bhasin S, Storer T, Asbel-Sethi N (1998) Effects of testosterone replacement with a nongenital transdermal system, androderm, in human immunodeficiency virus-infected men with low testosterone levels. Journal of Clinical Endocrinology and Metabolism 83, 3155–3162.
Bhasin S, Storer T & Javanbakht M (2000) Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. Journal of the American Medical Association 283, 763–770.
Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux N, Mandelbrot L, Desguerre I, Rötig A, Mayaux MJ & Delfraissy JF (1999) Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354, 1084–1089.
Bonnet E, Lepec R & Bluteau M (2000) A prospective, open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undectectable viral loads on protease inhibitor regimens for at least 6 months. In Seventh Conference on retroviruses and Opportunistic Infections. San Francisco, CA.
Brinkman K, Smeitink JA, Romijn JA & Reiss P (1999) Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet 354, 1112–1115.
Carbonnel F, Maslo C & Beaugerie L (1998) Effect of indinavir on HIV-related wasting. AIDS 12, 1777–1784.
Carr A, Samaras K, Chisholm DJ & Cooper DA (1998a) Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet 351, 1881–1883.
Carr A, Samaras K, Burton S, Law M, Freund J, Chrisholm D & Cooper DA (1998b) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS 12, 51–58.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chrisholm DJ & Cooper DA (1999) Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus: a cohort study. Lancet 353, 2093–2099.
Carr A, Miller J, Law M & Cooper DA (2000) A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, 25–32.
CDC (1987) Revised classification system for HIV infections and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 36, 1–15s.
CDC (1993) Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 41, 1–19.
Danner SA, Carr A & Leonard JM (1995) A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. The New England Journal of Medicine 333, 1528–1533.
Dowling S, Mulcahy F & Gibney M (1990) Nutrition in the management of HIV antibody positive patients: a longitudinal study of dietetic out-patient advice. European Journal of Clinical Nutrition 44, 823–829.
Dubé MP, Johnson DL & Currier JS (1997) Protease inhibitor-associated hyperglycemia. Lancet 350, 713–714.
Ellis KJ & Bell SJ (1999) Bioelectrical impedance methods in clinical research: a follow-up to the NIH Technology Assessment Conference. Nutrition 15, 874–880.
Gallet B, Pullik M & Genet P (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1958–1959.
Garg A & Grundy SM (1990) Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. Journal of the American Medical Association 264, 723–726.
Garg A (1998) Dyslipoproteinemia and diabetes. Endocrinology and Metabolism Clinics of North America 27, 613–625.
Gharakanian S, Salhi Y & Adda N (2000). Identification of fat redistribution metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI and absence of significant modification following PI substitution. In Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Gibson RS et al. (1990) Principles of Nutritional Assessment, New York, NY: Oxford University Press.
Goebel F & Walli RK (2000) A novel use of abacavir to simplify therapy in PI experienced patients successfully treated with HAART: CNA30017. In Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Goujard C, Lascaux AS, Dulioust A, Boué F, Delfraissy JF, Sobel A & Boufassa F. (2000) Lipodystrophy in PI-naive patients treated with RTI combinations: frequency and risk factors. In: Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Grinspoon S, Corcoran C & Miller K (1997) Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. Journal of Clinical Endocrinology and Metabolism 82, 1332–1337.
Grinspoon S, Corcoran C & Askari H (1998) Effects of androgen administration in men with AIDS wasting: a randomized, placebo-controlled trial. Annals of Internal Medicine 129, 18–26.
Grinspoon S, Corcoran C & Rosenthal D (1999) Quantitative assessment of cross-sectional muscle area, functional status and strength in men with the AIDS wasting syndrome. Journal of Clinical Endocrinology and Metabolism 84, 201–206.
Grunfeld C, Kotler DP & Shigenaga JK (1991) Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. American Journal of Medicine 90, 154–162.
Grunfeld C, Pang M & Shimizu L (1992a) Resting energy expenditure, caloric intake and weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. American Journal of Clinical Nutrition 55, 455.
Grunfeld C, Pang M & Doerrler W (1992b) Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology and Metabolism 74, 1045–1052.
Guenter P, Muurahainen N & Simons G (1993) Relationships among nutritional status, disease progression and survival in HIV infection. Journal of Acquired ImmunoDeficiency Syndrome 6, 1130.
Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A & Grinspoon S (2000a) Fasting hyperinsulinemia in HIV-infected men: relationship to body composition, gonadal function and protease-inhibitor use. Journal of Clinical Endocrinology and Metabolism 85, 35–41.
Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N & Grinspoon S (1999) Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology and Metabolism 84, 1932–1937.
Hadigan C, Corcoran C & Basgoz N (2000b) Metformin in the treatment of HIV lipodystrophy syndrome. Journal of the American Medical Association 284, 472–477.
Haffner SM & Miettinen H (1997) Insulin resistance implications for type II diabetes mellitus and coronary heart disease. American Journal of Medicine 103, 152–162.
Hellerstein MC, Grunfeld C & Wu F (1993) Increased de novo lipogenesis in human immunodeficiency virus infection. Journal of Clinical Endocrinology and Metabolism 7, 559.
Henry K, Melroe H & Huebsch J (1998a) Severe premature coronary artery disease with protease inhibitors. Lancet 351, 1328.
Henry K, Melroe H & Huebsch J (1998b) Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352, 1031–1032.
Hokanson JE & Austin MA (1996) Plamas triglyceride level is a risk factor for cardiovascular disease independent of HDL cholesterol level: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk 3, 213–219.
Hommes MJT, Romijn JA, Endert E, Eeftinck-Schattenkenkerk JKM & Sauerwein HP (1991) Insulin sensitivity and insulin clearance in human immunodeficiency virus infected men. Metabolism 40, 651.
Ireton-Jones CS et al. (1998) Evaluation of outcomes for patients with AIDS receiving home total parenteral nutrition. Nutrition 14, 731–735.
Kotler DP, Wang J & Pierson R (1985) Studies of body composition in patients with acquired immunodeficiency syndrome. American Journal of Clinical Nutrition 42, 1255–1265.
Kotler DP, Tierney AR, Wang J & Pierson RE (1989) Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. American Journal of Clinical Nutrition 50, 444–447.
Kotler D, Tierney AR & Ferraro R (1991) Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. American Journal of Clinical Nutrition 53, 149.
Lo JC, Mulligan K, Tai VW, Algren H & Schambelan M (1998) Buffalo hump in men with HIV 1 infection. Lancet 351, 867–870.
Lukaski HC, Bolonchuk WW, Hall CB & Siders WA (1986) Validation of tetra polar bioelectrical impedance method to assess human body composition. Journal of Applied Physiology 60, 1327–1332.
Lumpkin MM (1997) Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treament of human immunodeficiency virus (HIV). FDA Public Health Advisory.
Macallan DC, Noble C & Baldwin C (1993) Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. American Journal of Clinical Nutrition 58, 417.
Macallan DC, Noble C & Baldwin C (1995) Energy expenditure and wasting in human imunodeficiency virus infection. New England Journal of Medicine 333, 83–88.
Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA & Weller IVD (1999) Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 13, 735–737.
Martinez E, Conget I & Lozano L (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13, 805–810.
Melchior JC, Raguin G & Boulier A (1993) Resting energy expenditure in HIV infected patients. Comparison between patients with and without secondary infections. American Journal of Clinical Nutrition 57, 614.
Melchior JC, Chastang C & Gelas P (1996) Efficacy of 2 month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. AIDS 10, 379–384.
Melchior JC, Gelas P, Carbonnel F & Zazzo JF (1998) Improved survival by home total parenteral nutrition in AIDS patients: follow-up of a controlled randomized prospective trial. AIDS 12, 336–337.
Melchior JC, Niyongabo T & Henzel D (1999) Malnutrition and wasting, immunodepression, and chronic inflammation as independant predictors of survival in HIV-infected patients. Nutrition 15, 865–869.
Mhiri C, Belec L, DiCostanza B, Georges A & Gherardi R (1992) The slim disease in African patients with AIDS. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 303–306.
Miller KD, Jones E & Yanovski JA (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871–875.
Mizock BA & Falk JL (1992) Lactic acidosis in critical illness. Critical Care Medicine 20, 80–93.
Mulligan K, Grunfeld C, Hellerstein M, Neese RA & Schambelan M (1993) Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immuodeficiency virus infection. Journal of Clinical Endocrinology and Metabolism 77, 956–962.
Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN & Schambelan M (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. Journal of Acquired Immunodeficiency Syndrome 23, 35–43.
Nahlen BL, Chu SY, Nwanyanwu OC, Berkelman RL, Martinez SA & Rullan JV (1993) HIV wasting syndrome in the United States. AIDS 7, 183.
Niyongabo T, Melchior JC, Henzel D, Bouchard O & Larouze B (1999) Comparison of methods for assessing nutritional status in HIV-infected adults. Nutrition 15, 740–743.
Ockenga J, Süttmann U & Selberg O (1996) Percutaneous endoscopic gastrostomy in AIDS and control patients: risks and outcomes. American Journal Gastroenterology 91, 1817–1822.
Opravil M, Yerly S & Lazzarin A (2000) Protease inhibitor class-sparing maintenance therapy with abacavir + lamivudine + zidovudine in patients with long-term suppression of HIV-1 RNA. In Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Oster M, Enders S & Samuels S (1994) Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine 121, 400–408.
Ott M, Lembcke B & Fisher H (1993) Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. American Journal of Clinical Nutrition 57, 15.
Paton NI, Castello-Branco LR (1999) Impact of tuberculosis on the body composition of HIV-infected men in Brazil. Journal of Acquired Immunodeficiency Syndrome 20, 265–271.
Paton N, Newton PJ & Sharpstone D (1999) Short-term growth hormone administration at the time of opportunistic infections in HIV-positive people. AIDS 13, 1995–2002.
Periard D, Telenti A & Sudre P (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700–705.
Perlenicek JP, Graham NM & He YD (1996) Weight loss prior to clinical AIDS as predictor of survival. Multicenter AIDS cohort Study Investigators. Journal of Acquired Immunodeficiency Syndrome 10, 366.
Purnell JQ, Zambon A & Knopp H (2000) Effects of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14, 51–57.
Roubenoff R, McDermott A, Weiss L, Heflin T, Cloutier GJ, Wood M & Gorbach S (1999) Short-term progressive resistance training increases strenght and lean body mass in adults infected with human immunodeficiency virus. AIDS 13, 231–239.
Rozenbaum W, Molina JM & Delfraissy JF (2000) Improvment of lipodystrophy in HIV-1 infected subjects switching from 2 NRTI/PI to 2NRTI/Abacavir (French substudy, CNA30017). In Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Ruiz L, Negredo E & Domingo P (2000) Clinical, virological and immunological benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy: 36-week follow-up. In Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Saint-Marc T, Partisani M, Poizot-Martin I, Rouvière O, Bruno F, Avallaneda R, Lang JM, Gastaut JA & Touraine JL (1999) A syndrome of peripheral fat wasting in patients receiving long-term nucleoside analogue therapy. AIDS 13, 1659–1667.
Safrin S & Grunfeld C (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13, 2493–2505.
Schambelan M, Mulligan K & Grunfeld C (1996) Recombinant human growth hormone in patients with HUV-associated wasting. Annals of Internal Medicine 125, 873–882.
Serwadda D, Mugerwa R & Sewanfambo N (1985) Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 2, 849–852.
Shabert J, Winslow C, Lacey J & Wilmore D (1999) Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized double-blind controlled trial. Nutrition 15, 860–864.
Silva M, Skolnik P & Gorbach S (1998) The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12, 1645–1651.
Strawford A, Barbieri T & Neese R (1999) Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. Journal of Acquired ImmnunoDeficiency Syndrome and Human Retrovirology 20, 137–146.
Sullivan AK & Nelson MR (1997) Marked hyperlipidaemia in ritonavir therapy. AIDS 11, 938–939.
Süttmann U, Ockenga J & Selberg O (1995) Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. Journal of Acquired Immunodeficiency Syndrome 8, 239.
Tebas P, Yarasheski K & Powderly WG (2000) A prospective open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months. In Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
Vittecoq D, Escaut L & Monsuez JJ (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1959.
Von Roenn J, Amstrong D & Kotler D (1994) Megestrol acetate in patients with AIDS-related cachexia. Annals of Internal Medicine 121, 393–399.
Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner , Landgraf R & Goebel FD (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 12, 167–173.
Wanke C, Silva M, Knox T, Forrester J, Speigelman D & Gorbach S (2000) Weight loss and wasting remain common complications in individuals infected with HIV in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 31, 803–805.
Wheeler DA, Givert CL & Launer CA (1998) Weight loss as a predictor of survival and disease progression in HIV infection. Journal of Acquired Immunodeficiency Syndrome and Human Retrovirology 18, 80–85.
Yarasheski K, Zachwieja J & Gisher J (1998) Increased plasma Gln and Leu R and inappropriately low muscle protein synthesis rate in AIDS wasting. American Journal of Physiology 275, 577–583.